merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Safety risks, including swelling and bleeding in the brain</answer>

<question_number>2</question_number>
<answer>Some experts worry it might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>3</question_number>
<answer>No correlation between the removal of amyloid plaques and the clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>N/A</answer>
<other>The article mentions the difference in rates but doesn't describe the impact on safety perception</other>

<question_number>5</question_number>
<answer>Patients can stop taking Kisunla after amyloid is cleared, unlike Leqembi which continues indefinitely</answer>

<question_number>6</question_number>
<answer>N/A</answer>
<other>The article only mentions expert concern about discouraging trial participation, not actual patient impact</other>

<question_number>7</question_number>
<answer>Monthly dosing compared to Leqembi's bi-weekly dosing</answer>

<question_number>8</question_number>
<answer>amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>